Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in Italy
Objectives Dynamics of antibody responses following SARS-CoV-2 infection are controversial in terms of immunity and persistence. We aimed to assess longitudinally the trend of antibody serological titres, their correlation with clinical severity as well as clinical reinfection during a follow-up.Des...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-07-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/7/e056370.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576623206989824 |
|---|---|
| author | Iosief Abraha Paolo Eusebi Marta Micheli Antonella Germani Erica Pasquarelli Sofia Pascolini Rossana Antonietti Sandro Argenti Alessandra Fioravanti Elisa Martini Luana Aristei Paola Mancinelli Maria Letizia Ottaviani Martina Roselli Milena Barzacca Erika Belardinelli |
| author_facet | Iosief Abraha Paolo Eusebi Marta Micheli Antonella Germani Erica Pasquarelli Sofia Pascolini Rossana Antonietti Sandro Argenti Alessandra Fioravanti Elisa Martini Luana Aristei Paola Mancinelli Maria Letizia Ottaviani Martina Roselli Milena Barzacca Erika Belardinelli |
| author_sort | Iosief Abraha |
| collection | DOAJ |
| description | Objectives Dynamics of antibody responses following SARS-CoV-2 infection are controversial in terms of immunity and persistence. We aimed to assess longitudinally the trend of antibody serological titres, their correlation with clinical severity as well as clinical reinfection during a follow-up.Design Longitudinal cohort, 12 months follow-up study.Setting USL Umbria 2.Participants Consecutive subjects aged 15–75 who were discharged with the diagnosis of Sars-Cov-2 from the hospitals of the AUSL Umbria 2, or resulted positive to a PCR test for SARS-CoV-2 infection with or without symptoms were recruited. SARS-CoV-2 serological testing for antibodies targeting the Nucleocapside and Spike proteins were determined.Results Of 184 eligible subjects, 149 were available for evaluation: 17 were classified as oligo/asymptomatic, 107 as symptomatic, 25 as hospital admitted. Participants differed in terms of signs and symptoms as well as treatment. Overall there was a significant difference in terms of antibody titres between groups (anti-S: p<0.00; anti-N: p=0.019). Median anti-S titres in the symptomatic and hospital admitted participants were significantly higher compared with the oligo/asymptomatic participants. During follow-up, the median titre of anti-S antibodies did not show significant variations (p=0.500) and the difference within groups remained constant overtime. Subjects that showed an anti-S titre above the threshold of 12 U/mL were 88.7% at first visit and 88.2% at last follow-up. Anti-N values were higher in the hospital admitted participants compared with the other two groups. Anti-N titre reduced constantly overtime (p<0.001) and across the three groups of participants. The percentage of the subjects with serological titre above threshold (<1.4 U/mL) decreased from 74.5%% to 29.2% (p<0.001). None of the participants developed clinically evident reinfection.Conclusion Anti-N and anti-S correlate well with clinical severity. While anti-N declines overtime, anti-S antibodies persist for at least 1 year. |
| format | Article |
| id | doaj-art-6f90b3b7001e4d619eb343561dd8dbbd |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-6f90b3b7001e4d619eb343561dd8dbbd2025-01-31T01:00:11ZengBMJ Publishing GroupBMJ Open2044-60552022-07-0112710.1136/bmjopen-2021-056370Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in ItalyIosief Abraha0Paolo Eusebi1Marta Micheli2Antonella Germani3Erica Pasquarelli4Sofia Pascolini5Rossana Antonietti6Sandro Argenti7Alessandra Fioravanti8Elisa Martini9Luana Aristei10Paola Mancinelli11Maria Letizia Ottaviani12Martina Roselli13Milena Barzacca14Erika Belardinelli151Health Planning Service, Regional Health Authority of Umbria, Department of Epidemiology, 06124 Perugia, ItalyresearcherServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyServizio Immunotrasfusionale, Azienda Unità Sanitaria Locale Umbria 2, Foligno (PG), ItalyObjectives Dynamics of antibody responses following SARS-CoV-2 infection are controversial in terms of immunity and persistence. We aimed to assess longitudinally the trend of antibody serological titres, their correlation with clinical severity as well as clinical reinfection during a follow-up.Design Longitudinal cohort, 12 months follow-up study.Setting USL Umbria 2.Participants Consecutive subjects aged 15–75 who were discharged with the diagnosis of Sars-Cov-2 from the hospitals of the AUSL Umbria 2, or resulted positive to a PCR test for SARS-CoV-2 infection with or without symptoms were recruited. SARS-CoV-2 serological testing for antibodies targeting the Nucleocapside and Spike proteins were determined.Results Of 184 eligible subjects, 149 were available for evaluation: 17 were classified as oligo/asymptomatic, 107 as symptomatic, 25 as hospital admitted. Participants differed in terms of signs and symptoms as well as treatment. Overall there was a significant difference in terms of antibody titres between groups (anti-S: p<0.00; anti-N: p=0.019). Median anti-S titres in the symptomatic and hospital admitted participants were significantly higher compared with the oligo/asymptomatic participants. During follow-up, the median titre of anti-S antibodies did not show significant variations (p=0.500) and the difference within groups remained constant overtime. Subjects that showed an anti-S titre above the threshold of 12 U/mL were 88.7% at first visit and 88.2% at last follow-up. Anti-N values were higher in the hospital admitted participants compared with the other two groups. Anti-N titre reduced constantly overtime (p<0.001) and across the three groups of participants. The percentage of the subjects with serological titre above threshold (<1.4 U/mL) decreased from 74.5%% to 29.2% (p<0.001). None of the participants developed clinically evident reinfection.Conclusion Anti-N and anti-S correlate well with clinical severity. While anti-N declines overtime, anti-S antibodies persist for at least 1 year.https://bmjopen.bmj.com/content/12/7/e056370.full |
| spellingShingle | Iosief Abraha Paolo Eusebi Marta Micheli Antonella Germani Erica Pasquarelli Sofia Pascolini Rossana Antonietti Sandro Argenti Alessandra Fioravanti Elisa Martini Luana Aristei Paola Mancinelli Maria Letizia Ottaviani Martina Roselli Milena Barzacca Erika Belardinelli Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in Italy BMJ Open |
| title | Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in Italy |
| title_full | Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in Italy |
| title_fullStr | Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in Italy |
| title_full_unstemmed | Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in Italy |
| title_short | Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in Italy |
| title_sort | temporal trends and differences of sars cov 2 specific antibody responses in symptomatic and asymptomatic subjects a longitudinal study from umbria in italy |
| url | https://bmjopen.bmj.com/content/12/7/e056370.full |
| work_keys_str_mv | AT iosiefabraha temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT paoloeusebi temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT martamicheli temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT antonellagermani temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT ericapasquarelli temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT sofiapascolini temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT rossanaantonietti temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT sandroargenti temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT alessandrafioravanti temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT elisamartini temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT luanaaristei temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT paolamancinelli temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT marialetiziaottaviani temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT martinaroselli temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT milenabarzacca temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly AT erikabelardinelli temporaltrendsanddifferencesofsarscov2specificantibodyresponsesinsymptomaticandasymptomaticsubjectsalongitudinalstudyfromumbriainitaly |